House panel calls on Mylan CEO to explain EpiPen prices at Sept. 21 hearing

Mylan CEO Heather Bresch will appear before the U.S. House Committee on Oversight and Government Reform on Sept. 21 to explain why EpiPens, which cost $57 per pen in 2007, now run for more than $600 for a two-pack, according to Bloomberg.

The panel also called on Douglas Throckmorton, MD,, deputy director at the Food and Drug Administration's Center for Drug Evaluation and Research, for answers regarding delays in the approval of a competing epinephrine auto-injector.

"There is justified outrage from families and schools across the country struggling to afford the high cost of EpiPens," committee Chairman and Rep. Jason Chaffetz (R-Utah) and Rep. Elijah Cummings (D-Md.) said in a statement.

The Senate Permanent Select Subcommittee on Investigations has also opened a preliminary inquiry on Canonsburg, Pa.-based Mylan.

More articles on supply chain:

Market exclusivity main factor in high drug prices, study finds
Supply chain salaries to increase nearly 3% in 2017
5 myths about the EpiPen controversy


Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars